Skip to Content
MilliporeSigma
  • Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.

Cancer letters (2015-02-28)
Zhenyu Xiao, Haniee Chung, Babak Banan, Pamela T Manning, Katherine C Ott, Shin Lin, Benjamin J Capoccia, Vijay Subramanian, Ronald R Hiebsch, Gundumi A Upadhya, Thalachallour Mohanakumar, William A Frazier, Yiing Lin, William C Chapman
ABSTRACT

Human hepatocellular carcinoma (HCC) has a high rate of tumor recurrence and metastasis, resulting in shortened survival times. The efficacy of current systemic therapies for HCC is limited. In this study, we used xenograft tumor models to investigate the use of antibodies that block CD47 and inhibit HCC tumor growth. Immunostaining of tumor tissue and HCC cell lines demonstrated CD47 over-expression in HCC as compared to normal hepatocytes. Macrophage phagocytosis of HCC cells was increased after treatment with CD47 antibodies (CD47mAbs) that block CD47 binding to SIRPα. Further, CD47 blockade inhibited tumor growth in both heterotopic and orthotopic models of HCC, and promoted the migration of macrophages into the tumor mass. Our results demonstrate that targeting CD47 by specific antibodies has potential immunotherapeutic efficacy in human HCC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Carboxy-fluorescein diacetate N-succinimidyl ester, for fluorescence, ≥95.0% (HPLC)
Sigma-Aldrich
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Sigma-Aldrich
Potassium hydride, in paraffin
Sigma-Aldrich
Potassium hydride, 30 wt % dispersion in mineral oil
Sigma-Aldrich
Potassium, chunks (in mineral oil), 98% trace metals basis